Загрузка...
Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
Over the last few years, dramatic changes have occurred in the treatment of chronic lymphocytic leukemia (CLL). The current standard for young and fit patients with CLL remains chemoimmunotherapy, namely the fludarabine, cyclophosphamide, and rituximab (FCR) regimen. However, novel oral therapies ar...
Сохранить в:
| Опубликовано в: : | Onco Targets Ther |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5308588/ https://ncbi.nlm.nih.gov/pubmed/28223822 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S102646 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|